Intravesical, radiofrequency-induced chemohyperthermia in the treatment of non-muscle invasive bladder cancer

1. World Health Organization. Population Fact Sheets: World https://gco.iarc.fr/today/data/factsheets/ populations/900-world‑fact‑sheets. pdf; 2018 [otevřeno 25 dubna 2022].

2. Woldu SL, Bagrodia A, Lotan Y. Guideline of guidelines: non‑muscle- invasive bladder cancer. BJU Int. 2017; 119: 371–80.

3. Sylvester RJ. Natural history, recurrence, and progression in superficial bladder cancer. Scientific World Journal. 2006; 6: 2617–2625.

4. Babjuk M, Burger M, Compérat E, et al. EAU Guidelines on Non Muscle Invasive Urothelial Carcinoma of the Bladder: Update 2022, http://uroweb.org/guidelines/compilations‑of‑all‑guidelines/.

5. Shore ND, Palou Redorta J, Robert G, et al. Non‑muscle‑invasive bladder cancer: an overview of potential new treatment options. Urol Oncol. 2021; 39(10): 642–663.

6. Campodonico F, Di Stasi S, Lev GM, et al. Intravesical Chemotherapy and Chemohyperthermia in Non‑Muscle‑Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics. Curr Drug Metab. 2017; 18(7): 657–665.

7. Rigatti P, Lev A, Colombo R. Combined intravesical chemotherapy with mitomycin C and local bladder microwave‑induced hyperthermia as a preoperative therapy for superficial bladder tumors. A preliminary clinical study. Eur Urol. 1991; 20(3): 204–10.

8. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol. 2003; 21(23): 4270–4276.

9. van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency‑induced hyperthermia combined with chemotherapy for non‑muscle‑invasive bladder cancer. Int J Hyperthermia. 2016; 32(4): 351–62.

10. England HR, Anderson JD, Minasian H, et al. The therapeutic application of hyperthermia in the bladder. Br J Urol. 1975; 47: 849–52.

11. Tan WP, Longo TA, Inman BA. Heated Intravesical Chemotherapy: Biology and Clinical Utility. Urol Clin North Am. 2020; 47(1): 55–72.

12. Diederich CJ. Thermal ablation and high‑temperature thermal therapy: overview of technology and clinical implementation. Int J Hyperthermia. 2005; 21(8): 745–53.

13. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. Crit Rev Oncol Hematol. 2002; 43(1): 33–56.

14. Haveman J, Smals OA, Rodermond HM. Effects of hyperthermia on the rat bladder: a pre‑clinical study on thermometry and functional damage after treatment. Int J Hyperthermia. 2003; 19: 45–57.

15. Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. Adv Drug Deliv Rev. 2020; 163–164: 84–97.

16. Issels RD. Hyperthermia adds to chemotherapy. European journal of cancer (Oxford, England: 1990). 2008; 44(17): 2546–2554.

17. Maeda H, Tsukigawa K, Fang J. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next‑Generation Chemotherapeutics and Photodynamic Therapy‑ -Problems, Solutions, and Prospects. Microcirculation (New York, NY: 1994). 2016; 23(3): 173–182.

18. Au JL, Wientjes MG. Combination intravesical hyperthermia and chemotherapy for bladder cancer. Oncology (Williston Park). 2010; 26: 1155–60.

19. Inman BA, Etienne W, Rubin R, et al. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. Int J Hyperthermia. 2013; 29: 206–10.

20. van der Heijden AG, Dewhirst MW. Effects of hyperthermia in neutralising mechanisms of drug resistance in non‑muscle‑invasive bladder cancer. Int J Hyperthermia. 2016; 32(4): 434–45.

21. Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels. Int J Nanomed. 2013; 8: 351–63.

22. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. Nature reviews Immunology. 2015; 15(6): 335–349.

23. Milani V, Noessner E, Ghose S, et al. Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 2002; 18(6): 563–575.

24. Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin‑C with and without hyperthermia. World J Urol. 2015; 33: 1411–17.

25. Ware MJ, Tinger S, Colbert KL, et al. Radiofrequency treatment alters cancer cell phenotype. Sci Rep. 2015; 5: 12083.

26. van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2018; 34(7): 988–993.

27. Curley SA, Palalon F, Sanders KE, Koshkina NV. The effects of non‑invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. Int J Environ Res Public Health. 2014; 3: 11(9): 9142–53.

28. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non muscle invasive bladder cancer: A systematic review. Eur Urol. 2011; 60: 81–93.

29. Brummelhuis ISG, Wimper Y, Witjes‑van Os HGJM, et al. Long‑Term Experience with Radiofrequency‑Induced Hyperthermia Combined with Intravesical Chemotherapy for Non‑Muscle Invasive Bladder Cancer. Cancers. 2021; 13: 377.

30. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for selected multifocal and unresectable superficial bladder tumors. J Urol. 1998; 159: 783–7.

31. Brisuda A, Babjuk M, Stolz J. Intravezikální chemoterapie s využitím tepelné energie u pacientů s uroteliálním karcinomem močového měchýře bez invaze svaloviny. Ces Urol. 2017; 21(2): 122–128.

32. Arends TJH, Nativ O, Maffezzini M, et al. Results of the first randomized controlled trial comparing intravesical radiofrequency induced chemohyperthermia with mitomycin‑C vs. BCG for adjuvant treatment of patients with intermediate‑and high‑risk non‑muscle invasive bladder cancer. Eur Urol. 2015; 14: e944.

33. Colombo R, Salonia A, Leib Z, et al. Long term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin C alone as adjuvant treatment for non muscle invasive bladder cancer (NMIBC). BJU Int. 2011; 107: 912–918.

34. Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette Guérin for adjuvant treatment of patients with Intermediate- and High risk Non Muscle invasive Bladder Cancer. Eur Urol. 2016; 69(6): 1046–1052.

35. van Valenberg FJP, Kajtazovic A, Canepa G, et al. Intravesical Radiofrequency‑Induced Chemohyperthermia for Carcinoma in Situ of the Urinary Bladder: A Retrospective Multicentre Study. Bladder Cancer. 2018; 4(4): 365–376.

36. Tan WS, Panchal A, Buckley L, et al. Radiofrequency‑induced Thermo‑chemotherapy Effect Versus a Second Course of Bacillus Calmette‑Guérin or Institutional Standard in Patients with Recurrence of Non‑muscle‑invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette‑Guérin Therapy (HYMN): A Phase III, Open‑label, Randomised Controlled Trial. Eur Urol. 2019; 75(1): 63–71.

37. Sri D, Lee HJ, El‑Gemmal S, et al. Cystectomy outcomes in patients who have failed Radiofrequency‑induced Thermo‑chemotherapeutic Effect Mitomycin‑C (RITE‑MMC) treatment for high‑risk non‑muscle invasive bladder cancer (HRNMIBC) – Does it complicate surgery and adversely impact oncological outcome? Urol Oncol. 2021; 39(5): 300.e15–300.e20.